CIC
What's Inside


College Links

 About

 Directory

 Employment

 Map/Directions

 Volunteer

Search

 

 

Make a Gift box


 

 
  Home > Current Clinical Trials > Small Animal Surgery
 

Small Animal Surgery

CVMVMC2 - image - 690x350 - lake dog

Welcome to the Small Animal Surgery Studies Page!

If you would like more information about a study, or think you would like to enroll your pet, contact the person listed under the study. You may also Contact Us at the CIC.

Currently open studies:
1. COAST Study: A Dose Ranging Study to Evaluate the Field Safety and Effectiveness of a Single Intra-articular Injection of an Investigational Drug in Companion Animal Dogs with Chronic, Moderate to Severe Stifle Joint Pain Associated with Osteoarthritis

2. Evaluation of Allogeneic Stem Cells as an Adjuvant Therapy for Osteoarthritis

COAST Study: A Dose Ranging Study to Evaluate the Field Safety and Effectiveness of a Single Intra-articular Injection of an Investigational Drug in Companion Animal Dogs with Chronic, Moderate to Severe Stifle Joint Pain Associated with Osteoarthritis

Current Status: Open and enrolling
Principal Investigator: Michael Conzemius, DVM, PhD, DACVS
Contact: Sara Pracht, study technician, at 612-626-3574, prach011@umn.edu

We are looking for healthy dogs with chronic OA in the stifle joint (knee).  Dogs should weigh 30 lbs or more, be 2 years old or more and have moderate to severe pain that has existed for 3 months or more.

Purpose of Study:

Pain from osteoarthritis (OA) can be debilitating and can impair a dog’s ability to perform simple daily tasks such as walking or climbing stairs. Commonly prescribed medications for OA pain have a short duration of action, may give incomplete relief, and can have potentially serious side effects. Many dogs require repeated doses of one or more therapies to control their pain, resulting in prolonged systemic exposure. Such exposure may cause adverse effects. An investigational drug is being developed as a single intra-articular (into the joint) injection therapy aimed at achieving long-lasting pain relief with a short duration of systemic exposure and few known side effects.

Description of Study:

  • Four randomly assigned groups: three doses of investigational drug and one of placebo
  • Screening visit with diagnostic tests and evaluations to see if the dog is eligible
  • Day 0 – a single injection into one knee joint under anesthesia
  • Visits – Screening, Day 0, 14, 28
  • After day 28, monthly visits to assess how long the study medication remains effective

The study covers costs of screening, study medication and study-related tests. Owners who complete the study are eligible for a $200 gift card after Day 28, and $50 for each monthly visit thereafter.

If you are interested in participating or in referring a dog for this study, please contact Sara Pracht above.

Return to top

Evaluation of Allogeneic Stem Cells as an Adjuvant Therapy for Osteoarthritis

Current Status: Open and enrolling
Investigators:
Michael Conzemius, DVM, PhD, DACVS
Kristina Kiefer, DVM, PhD
Contact: Sara Pracht, study technician, at 612-626-3574, prach011@umn.edu

Osteoarthritis (OA) is a non-reversible disease in which the joint loses cartilage and begins to ossify (become bone-like). This causes pain and therefore lameness. Current therapies involve weight control, pain management and physical therapy. Allogeneic stem cell therapy is currently being explored as a possible treatment for this disease. This involves collection of stem cells from fat in normal dogs undergoing routine surgeries (such as spay or neuter). Because the cells come from a dog other than your pet, they are called allogeneic (non-self). These cells are capable of becoming many kinds of cells, and reduce inflammation. In theory, these stem cells can differentiate into cartilage. We suspect that allogeneic stem cell therapy will decrease inflammation of joints affected by OA and slow down arthritic progression.

We are looking for adult dogs that have been diagnosed with OA through physical examination, blood work, urinalysis, and radiographs (x-rays). There are two paths or arms in the study:

  1. If one limb is most clinically affected, dogs will be assigned to either a treatment group or a control group. This arm of the study uses injections into the affected joint under mild sedation. Dogs also receive gait analysis at each visit, where they will be leash-walked over a force plate to assess the severity of the lameness. At the 12 week visit, dogs will recieve radiographs to determine the severity of OA.
    • The treatment group will be treated with an allogeneic stem cell injection into the joint (IA) at enrollment and again at 6 weeks. No sedation is required for this injection. There is a final visit at 12 weeks.
    • The control group will recieve a placebo (saline) injection IA at enrollment and at 6 weeks. At the final 12 week visit, if the dog had the placebo injections, the dog will have the oppportunity to receive allogeneic stem cell therapy if the owner wishes.
       
  2. If multiple limbs are affected, dogs will be assigned to a treatment group or a control group. This arm of the study uses intravenous stem (IV) cell injections and an activity monitor which the dog wears to determine activity levels. At the 12 week visit, dogs will recieve radiographs to determine the severity of OA.
    • The treatment group will be treated with allogeneic stem cells (IV) at enrollment and again at 6 weeks. No sedation is required for this injection. There is a final visit at 12 weeks.
    • The control group will recieve a placebo (saline) injection IV at enrollment and at 6 weeks. At the final 12 week visit, if the dog had the placebo injections, the dog will have the oppportunity to receive allogeneic stem cell therapy if the owner wishes.
       

For more information, please contact Sara Pracht above.

Return to top

  

 

 

Notice of Privacy Practices